Biotransformation of parathion in human liver: Participation of CYP3A4 and its inactivation during microsomal parathion oxidation

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 2, 1997, Pages 966-973

  Butler, Alison M ^a   Murray, Michael ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; KETOCONAZOLE; PARATHION; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TESTOSTERONE; TOLBUTAMIDE; TROLEANDOMYCIN; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BIOTRANSFORMATION; CATALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME METABOLISM; LYMPHOBLASTOID CELL; OXIDATION; PRIORITY JOURNAL;

ANILINE HYDROXYLASE; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CELL LINE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; KINETICS; LIVER; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; PARATHION; RATS; REGRESSION ANALYSIS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SUBSTRATE SPECIFICITY;

EID: 0030893296     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. ARTERBERRY, J. D., BONIFACI, R. W., NASH, E. W. AND QUINBY, G. E.: Potentiation of phosphorus insecticides by phenothiazine derivatives: Possible hazard, with report of a fatal case. JAMA 182: 848, 1962.
2. BACK, D. J., TJIA, J. F., KARBWANG, J. AND COLBERT, J.: In vitro inhibition of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br. J. Clin. Pharmacol. 26: 23-29, 1988.
3. BUTLER, A. M. AND MURRAY, M.: Inhibition and inactivation of constitutive cytochromes P450 in rat liver by parathion. Mol. Pharmacol. 43: 902-908, 1993.
4. CASHMAN, J. R., YANG, Z., YANG, L. AND WRIGHTON, S. A.: Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes. Drug Metab. Dispos. 21: 492-501, 1993.
5. CHANG, T. K. H., WEBER, G. F., CRESPI, C. L. AND WAXMAN, D. J.: Differential activation of cyclophosphamide and ifosfamide by cytochrome-P450-B and cytochrome-P450-3A in human liver microsomes. Cancer Res. 53: 5629-5637, 1993.
6. GOSSELIN, R. E., SMITH, R. P. AND HODGE, H. C.: In Clinical Toxicology of Commercial Products, 5th ed., pp. III-336-343. Williams & Wilkins, Baltimore, 1984.
7. HALPERT, J., HAMMOND, D. AND NEAL, R. A.: Inactivation of purified rat liver cytochrome P-450 during the metabolism of parathion (diethyl p-nitrophenyl phosphorothionate). J. Biol. Chem. 255: 1080-1089, 1980.
8. HUNTER, A. L. AND NEAL, R. A.: Inhibition of hepatic mixed-function oxidase activity in vitro and in vivo by various thiono-sulfur-containing compounds. Biochem. Pharmacol. 24: 2199-2205, 1975.
9. KAMATAKI, T. AND NEAL, R. A.: Metabolism of diethyl p-nitrophenyl phosphorothionate (parathion) by a reconstituted mixed-function oxidase enzyme system: studies of the covalent binding of the sulfur atom. Mol. Pharmacol. 12: 933-944, 1976.
10. KARALLIEDDE, L. AND SENANAYAKE, N.: Acute organophosphorus insecticide poisoning in Sri Lanka. Forensic Sci. Int. 36: 97-100, 1988.
11. KNODELL, R. G., HALL, S. D., WILKINSON, G. R. AND GUENGERICH, F. P.: Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241: 1112-1119, 1987.
12. KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. AND MEYER, U. A.: Oxidation of midazolam and triazolam by human liver cytochrome P450 IIIA4. Mol. Pharmacol. 36: 89-96, 1989.
13. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275. 1951.
14. MARRE, F., SANDERINK, C.-J., DE SOUSA, G., GAILLARD, C., MARTINET, M. AND RAHMANI, R.: Hepatic biotransformation of Docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res. 56: 1296-1302, 1996.
15. MORELLI, M. A. AND NAKATSUGAWA, T.: Inactivation in vitro of microsomal oxidases during parathion metabolism. Biochem. Pharmacol. 27: 293-299, 1978.
16. MURRAY, M.: Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. Mol. Pharmacol. 42: 931-938, 1992.
17. MURRAY, M. AND RYAN, A. J.: Inhibition and enhancement of mixed-function oxidases by nitrogen heterocycles. Biochem. Pharmacol. 31: 3002-3005. 1982.
18. MURRAY, M., WILKINSON, C. F. AND DUBE, C. E.: Effects of dihydrosafrole on cytochromes P-450 and drug oxidation in hepatic microsomes from control and induced rats. Toxicol. Appl. Pharmacol. 68: 66-76, 1983.
19. NORMAN, B. J., POORE, R. E. AND NEAL, R. A.: Studies of the binding of sulfur released in the mixed-function oxidase-catalyzed metabolism of diethyl pnitrophenyl phosphorothioate (parathion) to diethyl p-nitrophenyl phosphate (paraoxon). Biochem. Pharmacol. 23: 1733-1744, 1974.
20. OMURA, T. AND SATO, R.: The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239: 2370-2378, 1964.
21. PlCHARD, L., CURI-PEDROSA, R., BONFILS, C., JACQZ-AlGRAIN, E., DOMERGUE, J., JOYEUX, H., COSME, J., GUENGERICH, F. P. AND MAUREL, P.: Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol. Pharmacol. 47: 410-418, 1995.
22. PROUGH, R. A., BURKE, M. D. AND MAYER, R. T.: Direct fluorometric methods for measuring mixed-function oxidase activity. Methods Enzymol. 52: 372-37, 1978.
23. SEGEL, I. H.: Enzyme kinetics. In Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley and Sons, New York, 1975.
24. SHIMADA, T. AND GUENGERICH, F. P.: Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. U.S.A. 86: 462-465, 1989.
25. SHIMADA, T., IWASAKI, M., MARTIN, M. V. AND GUENGERICH, F. P.: Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/PSK1002. Cancer Res. 49: 3218-3228, 1989.
26. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. AND GUENGERICH, F. P.: individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423, 1994.
27. SULTATOS, L. G., COSTA, L. G. AND MURPHY, S. D.: Determination of organophosphorus insecticides, their oxygen analogs and metabolites by high pressure liquid chromatography. Chromatographia 15: 669-671, 1982.
28. SWINEY, D. C., RYAN, D. E., THOMAS, P. E. AND LEVIN, W.: Regioselective progesterone hydroxylation catalyzed by eleven rat hepatic cytochrome p-450 isozymes. Biochemistry 26: 7073-7083, 1987.
29. WOMAN, D. J., Ko, A. AND WALSH, C.: Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J. Biol. Chem. 258: 11937-11947, 1983.
30. YUN, C.-H-, WOOD, M., WOOD, A. J. J. AND GUENGERICH, F. P.: Identification of the pharmacogenetic determinants of alfentanil metabolism: Cytochrome P-450 3A4. Anesthesiology 77: 467-474, 1992.